DelveInsight says HLH drug market reaches $140 million

DelveInsight says the US hemophagocytic lymphohistiocytosis (HLH) market was worth about $140 million in 2024, reflecting a small but high-need patient population and outcomes that remain challenging even with aggressive care.

In a January 15 press release, the market-research firm estimated roughly 5,100 incident HLH cases in the USA in 2024 and argued that conventional regimens still carry substantial mortality ahead of hematopoietic stem cell transplantation, with toxicity, treatment failure, and relapse risk limiting longer-term survival.

DelveInsight also pointed to Swedish orphan drugmaker Sobi (STO: SOBI) as the only company with an approved HLH drug, Gamifant (emapalumab), and said the franchise has gained momentum after a label expansion in the USA. The firm noted that the US Food and Drug Administration approved the drug in June 2025 for HLH/macrophage activation syndrome linked to known or suspected Still’s disease.